Canagliflozin hemihydrate

Names

[ Name ]:
Canagliflozin hemihydrate

[Synonym ]:
(1S)-1,5-Anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol hydrate (2:1)
(2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol,hydrate
UNII-0SAC974Z85
canagliflozin hydrate
D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-, (1S)-, hydrate (2:1)
Invokana
TA-7284
Canagliflozin (hemihydrate)

Biological Activity

[Description]:

Canagliflozin 0.5 H2O(JNJ 28431754; TA 7284) is a highly potent and selective SGLT2 inhibitor for hSGLT2 with IC50 of 2.2 nM, exhibits 413-fold selectivity over hSGLT1.IC50 value: 2.2 nMTarget: SGLT2Canagliflozin(JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284) is an experimental drug being developed by Johnson & Johnson for the treatment of type 2 diabetes.Canagliflozin(JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284) is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.

[Related Catalog]:

Signaling Pathways >> Membrane Transporter/Ion Channel >> SGLT

Research Areas >> Metabolic Disease

[References]

[1]. Sumihiro Nomura et al. Discovery of Canagliflozin, a Novel C-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus J. Med. Chem., 2010, 53 (17), pp 6355-6360

[2]. Nicolle LE, Capuano G, Ways K, Usiskin K.Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.Curr Med Res Opin. 2012 Jul;28(7):1167-71.

[3]. Rosenstock J, et al. Canagliflozin DIA 2001 Study Group.Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.Diabetes Care. 2012 Jun;35(6):1232-8.

[4]. Liang Y, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.PLoS One. 2012;7(2):e30555.

[5]. Devineni D, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.Diabetes Obes Metab. 2012 Jun;14(6):539-45. doi: 10.1111/j.1463-1326.2012.01558.x.

[Related Small Molecules]